D. Diprimeo

发表

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers

M. Berger, S. Loi, J Zhang, 2023, Nature Communications.

Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

R. Bose, H. Rugo, C. Singer, 2022, Breast.

Targeting HER2 mutation–positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial.

M. Berger, S. Loi, D. Solit, 2022, Journal of Clinical Oncology.

Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects

M. Obaidi, Ai Li, D. Swearingen, 2017, British journal of clinical pharmacology.

Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.

M. Buyse, M. Gnant, H. Iwata, 2023, European journal of cancer.

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

S. Loi, M. Burkard, R. Bose, 2023, Annals of Oncology.

M. Burkard, D. Solit, H. Wildiers, 2022 .